The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

  • STATUS
    Recruiting
  • End date
    Sep 30, 2021
  • participants needed
    11000
  • sponsor
    Danish Heart Foundation
Updated on 22 January 2021
anticoagulants
rivaroxaban
vitamin k antagonist
noac
vitamin k
apixaban
edoxaban
dabigatran
anticoagulation therapy

Summary

No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-AF study is a nationwide cluster randomized cross-over study comparing efficacy and safety of the four NOACs, edoxaban, apixaban, rivaroxaban and dabigatran for oral anticoagulation in non-valvular atrial fibrillation across Danish hospitals and cardiology clinics.

Description

No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists, but such data are warranted to evaluate if the four NOACs are equal in stroke prevention without an additional cost of increased bleeding risk. Furthermore, classic randomized trials are highly selective, as elderly and/or fragile patients and patients with comorbidity are underrepresented. Therefore, there is a need of randomized trials that include a broader population of patients.

The DANNOAC-AF study is a nationwide cluster randomized cross-over study comparing efficacy and safety of the four NOACs, edoxaban, apixaban, rivaroxaban and dabigatran for oral anticoagulation in non-valvular atrial fibrillation (AF) across Danish hospitals and cardiology clinics. The aim of the present study is to: 1) examine if the four NOACs are equally effective in preventing strokes, death and hospitalizations without increasing the risk of major bleeding requiring hospitalization; 2) conduct a randomized study that includes elderly and fragile patients and patients with comorbidity that would otherwise not be included in a traditional randomized clinical trial.

For a variety of reasons, Danish hospitals and clinicians often prefer one particular NOAC. This can make work simpler for the busy clinician, although there may also be economic advantages on a local or a regional larger scale. For a period of two years, this study will replace this individually preferred selection with a random selection. The hospitals and clinics that participate in this study will be randomly selected to primarily use one specific NOAC for 6 months at a time during a total period of two years. This only applies to patients with non-valvular AF that are selected by the physician to be eligible for NOAC treatment.

Endpoints

  • Primary efficacy outcome: a composite endpoint of stroke, myocardial infarction, thromboembolic event or all-cause death.
  • Secondary efficacy outcomes: Stroke, myocardial infarction, thromboembolism or all-cause death
  • Primary safety outcome: bleeding requiring hospitalization.
  • Other effect measures:
    1. discontinuation of therapy.
    2. adherence to therapy.
    3. other reasons of admission to hospital than included in the primary and secondary endpoint.
  • Sensitivity analyses:
    1. primary endpoint stratified by gender.
    2. primary endpoint stratified by age (65, 65-75, >75 years of age).
    3. primary endpoint stratified by levels of the CHA2DS2VASc score (0-1, 2-3, >3).
    4. primary endpoint with exclusion of clusters with non-compliance greater than 20% of cluster randomization.
    5. primary endpoint where the actual treatment is used instead of the allocated treatment.
    6. primary safety endpoint stratified by HAS-BLED score.

Information of endpoints and comorbidity is obtained from the Danish National Patient Register based on ICD-10 diagnostic codes and information of vital status and date of death will be obtained from the Central Person Register. Drug discontinuation and adherence will be examined using information from the Danish Registry of Medicinal Product Statistics. The prespecified endpoints will be evaluated after 2 years as intention-to-treat analysis. In addition, the prespecified endpoints will be evaluated after 5 and 10 years.

A cluster is defined as a hospital or a cardiology clinic. The Clusters will be enrolled in the study from 1. of May 2017 to 1. October 2017.

Details
Condition Arrhythmia, Atrial Fibrillation, Atrial Fibrillation (Pediatric), Dysrhythmia
Treatment Rivaroxaban Oral Tablet, Dabigatran Etexilate Oral Capsule, Edoxaban Oral Tablet, Apixaban Oral Tablet
Clinical Study IdentifierNCT03129490
SponsorDanish Heart Foundation
Last Modified on22 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have Atrial Fibrillation?
Do you have any of these conditions: Atrial Fibrillation or Arrhythmia or Atrial Fibrillation (Pediatric) or Dysrhythmia?
A diagnosis of atrial fibrillation in outpatient clinic or as discharge diagnosis after hospitalization
A claimed prescription of a NOAC from a Danish pharmacy within 14 days of discharge or outpatient clinic visit

Exclusion Criteria

A prescription of a NOAC within 90 days prior to hospitalization or outpatient clinic visit for AF
Presence of a mechanic cardiac valve prosthesis
Patients with NOAC preference apart from preference consistent with current cluster randomized NOAC
Other contraindications mentioned in the "Summary of Product Characteristics" for the respective NOAC
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note